Nakamura Hiroaki, Domon Yuki, Inoue Tatsuya, Arakawa Naohisa, Yokoyama Tomihisa
Biological Research Laboratories II, R&D Division Daiichi-Sankyo Co. Ltd., Tokyo, Japan.
Neuroreport. 2009 Oct 28;20(16):1481-5. doi: 10.1097/WNR.0b013e32833283e6.
To evaluate the effect of angiotensin II type1 receptor blocker on nerve regeneration delay in diabetic rats, nerve regeneration was monitored by a pinch test on the crushed sciatic nerves of streptozotocin-induced diabetic rats. Nerve regeneration was significantly delayed in diabetic rats and was partly ameliorated by treatment with olmesartan medoxomil (3 mg/kg/day, orally). In the ipsilateral dorsal root ganglia, the mRNA level of insulin-like growth factor-1 and ciliary neurotrophic factor (CNTF) was downregulated, whereas the mRNA level of neurotrophin-3 and CNTF receptor was upregulated. Olmesartan medoxomil significantly enhanced the CNTF expression. These results showed that angiotensin II type1 receptor blocker treatment is effective on nerve regeneration delay in diabetic animals and may provide an effective therapy for clinical diabetic neuropathy.
为评估血管紧张素II 1型受体阻滞剂对糖尿病大鼠神经再生延迟的影响,通过对链脲佐菌素诱导的糖尿病大鼠坐骨神经挤压伤进行夹捏试验来监测神经再生情况。糖尿病大鼠的神经再生显著延迟,而奥美沙坦酯(3毫克/千克/天,口服)治疗可部分改善这种情况。在同侧背根神经节中,胰岛素样生长因子-1和睫状神经营养因子(CNTF)的mRNA水平下调,而神经营养因子-3和CNTF受体的mRNA水平上调。奥美沙坦酯显著增强了CNTF的表达。这些结果表明,血管紧张素II 1型受体阻滞剂治疗对糖尿病动物的神经再生延迟有效,可能为临床糖尿病性神经病变提供有效的治疗方法。